Socioeconomic status and the 25 × 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1·7 million men and women
Institute of Social and Preventive Medicine · University of Helsinki · +20 more institutions
Abstract
In 2011, WHO member states signed up to the 25 × 25 initiative, a plan to cut mortality due to non-communicable diseases by 25% by 2025. However, socioeconomic factors influencing non-communicable diseases have not been included in the plan. In this study, we aimed to compare the contribution of socioeconomic status to mortality and years-of-life-lost with that of the 25 × 25 conventional risk factors.
We did a multicohort study and meta-analysis with individual-level data from 48 independent prospective cohort studies with information about socioeconomic status, indexed by occupational position, 25 × 25 risk factors (high alcohol intake, physical inactivity, current smoking, hypertension, diabetes, and obesity), and mortality, for a total population of 1 751 479 (54% women) from seven high-income WHO member countries. We estimated the association of socioeconomic status and the 25 × 25 risk factors with all-cause mortality and cause-specific mortality by calculating minimally adjusted and mutually adjusted hazard ratios [HR] and 95% CIs. We also estimated the population attributable fraction and the years of life lost due to suboptimal risk factors.
Citation impact
- FWCI
- 121.58
- Percentile
- 100%
- References
- 37
Authors
84- SSSilvia StringhiniCorresponding
Institute of Social and Preventive Medicine
- CCCristian Carmeli
Institute of Social and Preventive Medicine
- MJMarkus Jokela
University of Helsinki
- MAMauricio Avendaño
Harvard University, King's College London, Harvard Global Health Institute
- PMPeter Muennig
Global Policy Institute, Columbia University
Topics & keywords
- Socioeconomic status
- Meta-analysis
- Medicine
- Environmental health
- Demography
- Gerontology
- Internal medicine
- Population
- Good health and well-being
Funding
- NSNational Science Foundation
- GGlaxoSmithKline
- ECEuropean CommissionAward: 633666
- SNSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungAwards: PZ00P3_167732, 323530_151479
- NNordForskAward: K013351
- MRMedical Research CouncilAwards: MR/K013351/1, K013351, MR/L01341X/1, MR/M501669/1
- EAEconomic and Social Research CouncilAwards: ES/M001660/1, ES/J023299/1
- FPFundação para a Ciência e a TecnologiaAwards: 323530_151479, SFRH/BPD/97015/2013
- SFStaatssekretariat für Bildung, Forschung und InnovationAwards: 633666, PZ00P3_167732
- H2Horizon 2020Award: 633666